Investorideas.com Newswire

Investorideas.com Newswire
Be one of the most talked about companies (stocks) on social media

Tuesday, August 24, 2010

Investorideas.com - BioSante Pharmaceuticals (NASDAQ: BPAX) Company Profile at Investorideas.com

Investorideas.com - BioSante Pharmaceuticals (NASDAQ: BPAX) Company Profile at Investorideas.com

BioSante is focused on developing innovative products for female sexual health and oncology

Subscribe to Investor Ideas Newswire
Visit this company: www.biosantepharma.com


August 24, 2010 - (Investorideas.com newswire) www.InvestorIdeas.com, an investor research portal covering multiple sectors including biotech stocks and pharma stocks, announces the new company profile for pharma stock BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) for interested investors.


BioSante (NASDAQ: BPAX ) is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies.
Visit BioSante’s profile on Investorideas.com: http://www.investorideas.com/CO/BPAX/ or visit the BioSante website at www.biosantepharma.com to learn more about BioSante.


Request News & Updates from BioSante (NASDAQ: BPAX) on the Investorideas.com sign up page: http://www.investorideas.com/Resources/Newsletter.asp
About our Biotech/Pharma Stocks portal:
BiotechIndustryStocks.com Portal is a global meeting place for investors and industry following the sector, within Investorideas.com. Global visitors use the site daily to research the latest news, articles, audio, research reports and our stock directories.Visit the Biotech stocks Directory
About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.


BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) was brought to Investorideas.com by Money Channel TV http://www.moneychannel.tv/. The Money Channel’s "Steve Crowley's American Scene" was launched from the Disney/MGM Radio Studios at the Walt Disney World Resort in June 1990. The American Scene has millions of listeners on its three-hour daily radio broadcasts through the mighty IRN/USA Radio Network affiliates, plus other affiliates. There also is a growing listening audience on the Internet worldwide. In addition in The Money Channel produces WallStreetCast, a half hour program airing on FOX Business. WallStreetCast has highlighted some of today’s top experts and advisors from Wall Street and some of the best public companies in the market. Steve Crowley interviews top experts, analysts, money managers and authors covering stocks, investments, business, the economy and trends, Small-Cap CEOs and much more. More than 200 Financial “Stars” are interviewed in constant rotation….from Steve Forbes, Tobin Smith, Beth Dater, Joe Battipaglia, Larry Kudlow plus many more.
Disclaimer: The BioSante Pharmaceuticals, Inc company profile is a paid for submission profile. Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions, company profile submissions and online advertising. http://www.investorideas.com/About/Disclaimer.aspDisclosure: http://www.investorideas.com/About/News/Clientspecifics.asp


For information about BioSante Pharmaceuticals, Inc.Contact:
The Trout Group LLCTricia Swanson(646) 378-2953; tswanson@troutgroup.com


For Additional Information about Investorideas.com:
C Van Zant: 800-665-0411 – cvanzant@investorideas.com
Source – Investorideas.com

Friday, August 13, 2010

Investorideas.com - BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Second Quarter 2010 Financial Results

Investorideas.com - BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Second Quarter 2010 Financial Results

Biotech/Pharma Stock News-


BioSante Pharmaceuticals (NASDAQ: BPAX) Reports Second Quarter 2010 Financial Results
Category: Investment

Subscribe to Investor Ideas Newswire
Visit this company: www.biosantepharma.com



LINCOLNSHIRE, Illinois - August 13, 2010 (Investorideas.com Newswire) - BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced its financial results for the second quarter of 2010.


The Company's cash and cash equivalents as of June 30, 2010 were approximately $46.4 million. BioSante incurred a net loss of approximately $10.8 million or ($0.17) per share for the quarter ended June 30, 2010, compared to a net loss of $4.6 million or ($0.17) per share for the same period in 2009. This increase in net loss was primarily a result of the expanded recruitment and conduct of the LibiGel® Phase III clinical development program. As a result of this focus on LibiGel development and the Company's planned acceleration of the LibiGel program, research and development expenses increased to $8.7 million and $18.1 million for the three and six month periods ended June 30, 2010 from $3.5 million and $6.6 million for the three and six month periods ended June 30, 2009.


"With more than $46 million in cash, we are aggressively recruiting, screening and enrolling new subjects in all three LibiGel Phase III clinical studies," stated Stephen M. Simes, president and chief executive officer of BioSante. "More than 2,000 women have been enrolled in the LibiGel cardiovascular and breast cancer safety study, and we expect to enroll our 2,500th subject early in the fourth quarter of this year. That important event will trigger the first statistical analysis by the independent DMC (data monitoring committee) to determine whether enrollment in the safety study is sufficient and complete, or if additional subjects must continue to be enrolled in order to demonstrate statistically the relative safety of LibiGel. The maximum number of subjects as per protocol is 4,000 women. We continue to target the submission of the LibiGel NDA (New Drug Application) by late 2011."


About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD) which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment, and Elestrin™ (estradiol gel) for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, which is marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines (GVAX), three of which have been granted orphan drug designation, and are currently in several Phase II clinical trials. Other products in development are Bio-T-Gel™, a testosterone gel for male hypogonadism, licensed to Teva Pharmaceuticals and an oral contraceptive in Phase II clinical development using BioSante patented technology. The company also is developing its calcium phosphate technology (CaP) for aesthetic medicine (BioLook™), among other uses, as well as seeking opportunities for its 2A/Furin and other technologies. Additional information is available online at: www.biosantepharma.com.


Forward-Looking Statements
To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to future operations and products, the timing of anticipated regulatory submissions and other statements identified by words such as "will," "potential," "could," "can," "believe," "intends," "continue," "plans," "expects," "anticipates," "estimates," "may," other words of similar meaning or the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the marketing success of BioSante's licensees or sublicensees; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.


For more information, please contact:
For Media:McKinney/ChicagoAlan Zachary(312) 944-6784 ext. 316; azachary@mckinneychicago.com
For Investors:The Trout Group LLCTricia Swanson(646) 378-2953; tswanson@troutgroup.com


More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Thursday, August 12, 2010

Investorideas.com - Sector Snapshot; Sector Research for Investors - Agriculture, Gold, Solar and Biotech Lead

Investorideas.com - Sector Snapshot; Sector Research for Investors - Agriculture, Gold, Solar and Biotech Lead


August 12, 2010 (Investorideas.com renewable energy/green newswire) Investor Ideas global investor research portal covering leading sectors, focusing on environment and water release a Sector snapshot for trading August 12th.



Sector Snapshot as of 12 Aug, 11:25am ET (delayed)
The following sectors showing gains for the day:
AGRICULTURE 2.2%
GOLD 1.9%
AIRLINE 1.8%
INTERNET 0.4%
HEALTHCARE 0.2%
SOLAR 0.2%
BIOTECH 0.1%



Investor Ideas also reported earlier this week that agriculture stocks and renewable energy stocks were within the top 10 investor searches inbound.Read news: http://www.investorideas.com/news/8112.asp



Investorideas.com was on the of the first investor sites covering investing in water and renewable energy stocks and has become a global go-to destination for investors researching the cleantech sector, with stock directories, company news, commentary from experts, research reports and industry resources and links.
With institutional research not being available to investors, the stock directories were created for investors to begin due diligence into leading sectors. Investorideas.com researches the sector each month for investors, adding new green stocks as they enter the space in Green IPO’s or reverses mergers.


Investor Ideas Members currently get login access to 11 stock directories including all of the cleantech stock directories. Other sectors included- biotech, defense, nanotech, energy and mining. Visit the Investor Ideas membership page to learn more at: http://www.investorideas.com/membership/


Renewable Energy Stocks Directory - Use our Green Stocks and Renewable Energy Stocks directory to Research Renewable Energy Stocks and Alternative Energy Stocks, Solar Stocks, Wind Stocks, Biofuels, Green Stocks, Green Funds and more. Our Directory includes publicly traded green stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM, Hong Kong and China and other leading Stock Exchanges. Our green stocks directory has over 1000 stocks and is growing each month! - Even the industry experts use our directory!


Water Stocks Directory - Global Water Stocks Directory of publicly traded water stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The stock directory features water stocks ranging from desalination companies to bottled water stocks, to infrastructure, water treatment and technology as well as other sub sectors. The directory in PDF format, features hyperlinks to stocks symbol(s), company's URL and company's description. For investors following water stocks this is one of the most comprehensive directories in the sector available.


Environment/ Lohas Stocks Directory - also includes a new LOHAS investor section Global Green Stocks Directory of Publicly traded Environmental Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory in PDF format, features hyperlinks to stocks symbol(s), company's URL and company's description.


Fuel Cell Stocks Directory - Global Directory of Publicly traded Fuel Cell Stocks listed on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading global Stock Exchanges. The directory includes small cap, micro cap as well as large cap NYSE listed stocks for review. For green investors looking for opportunities in the fuel cell sector, the comprehensive global directory in PDF format provides a great research tool with hyperlinks to stocks symbol(s), company's URL and company's description.
About Our Green Investor Portals:



www.RenewableEnergyStocks.com is one of several green investor portals within Investorideas.com, creating a meeting place for investors, public companies and industry leaders following developments in renewable and green energy. The site provides investors with stock news, exclusive articles and financial columnists, audio interviews, investor conferences, Blogs, research and a comprehensive global directory of stocks within the renewable energy sector. Investors can follow solar stocks commentary on our site with solar expert, J. Peter Lynch.


Visit the Investorideas.com Green Investor Portals: www.RenewableEnergyStocks.com, www.FuelCellCarNews.com, www.EnvironmentStocks.com and www.Water-Stocks.com all within the Investorideas.com hub.


Visit and Join the Investorideas.com cleantech social network- share and exchange green and cleantech investing ideas: http://investorideas.socialgo.com/
About InvestorIdeas.com:More about us: http://www.investorideas.com/About/
Disclaimer: Our sites do not make recommendations. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of information presented. All Information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is currently compensated by featured companies, news submissions and online advertising. www.InvestorIdeas.com/About/Disclaimer.asp


For Additional Information
Dawn Van Zant: 800-665-0411 - dvanzant@investorideas.comCali cvanzant@investorideas.com
Source - Investorideas.com

Investorideas.com - Leading Sectors include Biotech Stocks; OTCVolumeLeaders.com; ($0.14-$0.25): (OTCBB: IMGG), (OTCBB: ADXS), (OTCBB: SNGX), (OTCBB: TKOI)

Investorideas.com - Leading Sectors include Biotech Stocks; OTCVolumeLeaders.com; ($0.14-$0.25): (OTCBB: IMGG), (OTCBB: ADXS), (OTCBB: SNGX), (OTCBB: TKOI)

Sign up at OTC Volume leaders and get access to info on hundreds of the most active OTCBB companies by clicking the sign up link belowhttp://bit.ly/otcvolumeleaders
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS


Subscribe to Investor Ideas Newswire
Visit this company: www.otcvolumeleaders.com



Point Roberts, WA (Investorideas.com Newswire) August 12, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($0.14-$0.25) include Imaging3 Inc. (OTCBB: IMGG), Advaxis Inc. (OTCBB: ADXS), Soligenix, Inc. (OTCBB: SNGX), and Telkonet, Inc (OTCBB: TKOI).



Click below to sign up for Free list of Tomorrows Hot OTC Market Leaders!http://bit.ly/otcvolumeleaders
OTC / Market Commentary:
Sectors include Biotech Stocks
One of the OTCBB volume leader reports; Recent News: "Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company and Vibalogics GmbH, a German biologics manufacturing company, have agreed to co-develop a room temperature stable, processing technology for live vaccines originally engineered for Advaxis."


Market Snapshot: (at time of release)
Dow 10,327.14 -51.69 -0.50%

Nasdaq 2,190.67 -17.96 -0.81%
S&P 500 1,083.99 -5.48 -0.50%
10 Yr Bond(%) 2.7360% +0.5100
Oil 76.60 -1.42 -1.82%
Gold 1,214.70 +17.20 +1.44%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!


OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/


Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader



Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Tuesday, August 10, 2010

Investorideas.com - Oil and Gas Stocks and Biotech Stocks: OTC Volume Leaders Most Active ($2.00-$5.00): (OTCBB: ZARLF), (OTCBB: VYOG), (OTCBB: KMKCF), (OTCBB: NEOP)

Investorideas.com - Oil and Gas Stocks and Biotech Stocks: OTC Volume Leaders Most Active ($2.00-$5.00): (OTCBB: ZARLF), (OTCBB: VYOG), (OTCBB: KMKCF), (OTCBB: NEOP)

Follow more OTCBB stocks by clicking the sign up link below or go to otcvolumeleaders.com
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Category: Investment, Financial
Subscribe to Investor Ideas Newswire


Visit this company: www.otcvolumeleaders.com


Point Roberts, WA (Investorideas.com Newswire) August 10, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include Zarlink Semiconductor (OTCBB: ZARLF), Voyager Oil & Gas, Inc. (OTCBB: VYOG), CONTINENTAL MINERALS (KMKCF), and Neoprobe Corp. (NEOP).
Click below to sign up for Free list of Tomorrows Hot OTC Market Leaders!
http://bit.ly/otcvolumeleaders



OTC / Market Commentary:
Sectors include Biotech Stocks
One of the OTCBB volume leaders; Neoprobe Corp. (NEOP): "Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com."


Market Snapshot: (at time of release)
Dow 10,602.78 -95.97 -0.90%
Nasdaq 2,268.20 -37.49 -1.63%
S&P 500 1,116.33 -11.46 -1.02%
10 Yr Bond(%) 2.8160% -0.0600
Oil 79.89 -1.59 -1.95%
Gold 1,197.00 -3.70 -0.31%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.


Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/

Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader


Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp.

Friday, August 6, 2010

Investorideas.com - OTC Volume Leader Biotech Stocks and Green EnergyStocks; OTCVolumeLeaders.com; Most Active ($0.14-$0.25): (OTCBB: HDVY), (OTCBB: GHLV), (OTCBB: OOIL), (OTCBB: WNDT)

Investorideas.com - OTC Volume Leader Biotech Stocks and Green EnergyStocks; OTCVolumeLeaders.com; Most Active ($0.14-$0.25): (OTCBB: HDVY), (OTCBB: GHLV), (OTCBB: OOIL), (OTCBB: WNDT)

Follow more OTCBB stocks by clicking the sign up link below

Subscribe to Investor Ideas Newswire


Visit this company: www.otcvolumeleaders.com


Point Roberts, WA (Investorideas.com Newswire) August 6, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($0.14-$0.25) include Health Discovery Corp. (OTCBB: HDVY), Global Health Ventures Inc. (OTCBB: GHLV), OriginOil, Inc. (OTCBB: OOIL), and WindTamer Corporation (OTCBB: WNDT).



Click below to sign up for Free list of Tomorrows Hot OTC Market Leaders!http://bit.ly/otcvolumeleaders


OTC / Market Commentary:
Sectors include Green Energy Stocks and Biotech/Pharma Stocks
One of the OTCBB volume leader reports; Recent News: "WindTamer Corporation ("WindTamer" or the "Company) a developer and manufacturer of a patented new wind turbine technology and proprietary energy management system, announced today that it has signed a contract valued at $150,000 with Destiny USA Holdings, LLC to design, fabricate and install two rooftop-mounted 54GT-1000 WindTamer wind turbines for use at Carousel Center/Destiny USA in Syracuse, New York. This project is made possible via a federal grant to demonstrate renewable energy technologies."


Market Snapshot: (at time of release)
Dow 10,533.61 -141.37 -1.32%
Nasdaq 2,262.53 -30.53 -1.33%
S&P 500 1,110.09 -15.72 -1.40%
10 Yr Bond(%) 2.8240% -0.9100
Oil 81.12 -0.89 -1.09%
Gold 1,209.40 +9.80 +0.82%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.


OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!


OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/

Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader


Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.
Connect with Investorideas.com
Publish Your News - Send a release
Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Wednesday, August 4, 2010

Investorideas.com - Biotech Stocks and Tech Stocks: OTC Volume Leaders Most Active ($2.00-$5.00): (OTCBB: FKWL), (OTCBB: NEOP), (OTCBB: FTLUF), (OTCBB: MASC)

Investorideas.com - Biotech Stocks and Tech Stocks: OTC Volume Leaders Most Active ($2.00-$5.00): (OTCBB: FKWL), (OTCBB: NEOP), (OTCBB: FTLUF), (OTCBB: MASC)

Follow more OTCBB stocks by clicking the sign up link below or go to otcvolumeleaders.com
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS
Subscribe to Investor Ideas Newswire


Visit this company: www.otcvolumeleaders.com


Point Roberts, WA (Investorideas.com Newswire) August 4, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($2.00-$5.00) include Franklin Wireless Corp (OTCBB: FKWL), Neoprobe Corp. (OTCBB: NEOP), FUNTALK CHINA HLDG (OTCBB: FTLUF), and Material Sciences Corporation (OTCBB: MASC).


Click below to sign up for Free list of Tomorrows Hot OTC Market Leaders!http://bit.ly/otcvolumeleaders
OTC / Market Commentary:
Sectors include Biotech and Tech Stocks
One of the OTCBB volume leaders; Neoprobe Corp. (OTCBB: NEOP): "Neoprobe is a biomedical company focused on enhancing patient care and improving patient outcome by meeting the critical intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. Neoprobe currently markets the neoprobe® GDS line of gamma detection systems that are widely used by cancer surgeons. In addition, Neoprobe holds significant interests in the development of related biomedical systems and radiopharmaceutical agents including Lymphoseek® and RIGScan™ CR. Neoprobe’s subsidiary, Cira Biosciences, Inc., is also advancing a patient-specific cellular therapy technology platform called ACT. Neoprobe’s strategy is to deliver superior growth and shareholder return by maximizing its strong position in gamma detection technologies and diversifying into new, synergistic biomedical markets through continued investment and selective acquisitions. www.neoprobe.com"


Market Snapshot: (at time of release)
Dow 10,660.83 +24.45 +0.23%
Nasdaq 2,294.34 +10.82 +0.47%
S&P 500 1,123.62 +3.16 +0.28%
10 Yr Bond(%) 2.9460% +0.3200
Oil 82.21 -0.34 -0.41%
Gold 1,194.80 +9.60 +0.81%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.
OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!
OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.
Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader
Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.


Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.asp
Investorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp

Tuesday, August 3, 2010

Investorideas.com - Biotech OTCBB Stocks; OTC Volume Leaders; Most Active ($0.14-$0.25): (OTCBB: ADXS), (OTCBB: VHGI), (OTCBB: WNDT), (OTCBB: HNAB)

Investorideas.com - Biotech OTCBB Stocks; OTC Volume Leaders; Most Active ($0.14-$0.25): (OTCBB: ADXS), (OTCBB: VHGI), (OTCBB: WNDT), (OTCBB: HNAB)
Note to Editors: The Following Is an Investment Opinion Being Issued by OTC VOLUME LEADERS

Subscribe to Investor Ideas Newswire


Visit this company: www.otcvolumeleaders.com
Point Roberts, WA (Investorideas.com Newswire) August 3, 2010 - OTC VOLUME LEADERS reports on the most active trading stocks on the OTCBB. OTC Volume leaders ($0.14-$0.25) include ADVAXIS INC (OTCBB: ADXS), VHGI Holdings, Inc. (OTCBB: VHGI), WindTamer Corporation (OTCBB: WNDT), and Hana Biosciences, Inc. (OTCBB: HNAB).


Sign up for Free OTC Volume Leader Alerts!http://bit.ly/otcvolumeleaders
OTC / Market Commentary:
Sectors include Biotech
One of the OTCBB volume leader reports; Recent News:"Advaxis, Inc., the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has received formal permission from the Drugs Controller General India (DCGI) to conduct a Phase II clinical trial of ADXS11-001, the Company's flagship drug construct, among 110 women with advanced, metastatic cervical cancer that has progressed subsequent to treatment with cytotoxic therapy. 55 women will receive ADXS11-001 alone, 55 will receive a combined regimen of both ADXS11-001 and cytotoxic therapy."


Market Snapshot: (at time of release)
Dow 10,643.95 -30.43 -0.29%
Nasdaq 2,285.35 -10.01 -0.44%
S&P 500 1,121.28 -4.58 -0.41%
10 Yr Bond(%) 2.9070% -0.5600
Oil 82.34 +1.00 +1.23% Gold
1,188.50 +5.10 +0.43%


OTCBB Investors: Take the few minutes to register with us at To sign up for free Newsletter http://bit.ly/otcvolumeleaders and get access to info on hundreds of the most active OTCBB companies and keep up to date with developments of the companies.


OTC VOLUME LEADERS provides investors with daily market updates showcasing the most actively traded OTCBB Companies. We strive to provide you with the most up-to-date market information and activity by searching through hundreds of OTCBB companies in order to provide you information on the best of these companies. The goal is to continually find tomorrow’s market leading companies, today!

OTCVolumeleaders.com has not been compensated by any of the above mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks.


Please view the full disclaimer: http://www.otcvolumeleaders.com/Source http://www.otcvolumeleaders.com/

Follow OTC Volume Leaders on Twitter.com http://twitter.com/OTCVolumeLeader


Visit the OTC showcase profile at Investorideas.com Request News and Info on OTC Disclosure, Disclaimer/ OTC is a paid advertising client on Investorideas.com.
More Info:
Published at www.Investorideas.com - Global research by sectors
If you have any questions regarding information in this press release please contact the company listed in the press release.

Disclaimer: The following news is paid for and /or published as information only for our readers. Investorideas.com is a third party publisher of news and research .Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.
Investorideas.com Disclaimer: http://www.investorideas.com/About/Disclaimer.aspInvestorideas.com Disclosure: http://www.investorideas.com/About/News/Clientspecifics.asp